Lilly To Acquire Versanis To Improve Patient Outcomes In Cardiometabolic Diseases
07/14/23, 12:06 PM
Location
indianapolisIndustry
pharmaceutical
manufacturing
health care
biopharma
therapeutics
biotechnology
health care
Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.
Company Info
Location
Indianapolis, Indiana, United States
Company info
Lilly is a medicine company turning science into healing to make life better for people around the world. They have been pioneering life-changing discoveries for nearly 150 years, and today their medicines help more than 51 million people across the globe. Lilly is focused on redefining diabetes care, treating obesity, advancing the fight against Alzheimer's disease, providing solutions to immune system disorders, and transforming difficult-to-treat cancers into manageable diseases.